EGFR and central nervous system cancer: On the other hand, EGFR gain is significantly rarer overall in IDHmut gliomas (17 % grade II–III, 25 % grade IV) and CDKN2A loss is slightly lower (39 % grade II–III, 42 % grade IV) compared with IDHwt.